News & Events
< Back to News Overview
CogState Signs its First Agreement with Abbott
05 / 02 / 2007
Key points:
- CogState technology to be used for the first time by Abbott in a clinical trial
- CogState's contracted future revenue exceeds A$2.1m
- Abbott is a global healthcare company
CogState Ltd (ASX:CGS) announced today that it has signed its first agreement with Abbott for the use of CogState's cognitive testing technology and associated services, in a Phase I clinical trial.
Abbott is a global, broad-based healthcare company devoted to discovering new medicines, new technologies and new ways to manage health. Abbott has a substantial central nervous system portfolio of drugs in development.
CogState already has sales contracts with leading companies in the field of central nervous system drug development, including companies such as Pfizer, GlaxoSmithKline, Merck and Alza Corporation (part of Johnson & Johnson), whereby CogState's technology is used in their clinical trials.
Mr Brad O'Connor, Chief Executive Officer of CogState, said: "CogState continues to be focussed on growing our customer base of pharmaceutical companies. This agreement represents another success for the company and is an excellent example of the hard work we have been putting into expanding sales in the US market."
Following today's announced agreement with Abbott, the total value of CogState's contracted future revenue exceeds A$2.1m. Contracted future revenues are revenue amounts to be recognised in coming periods, from signed agreements currently in place.
- CogState technology to be used for the first time by Abbott in a clinical trial
- CogState's contracted future revenue exceeds A$2.1m
- Abbott is a global healthcare company
CogState Ltd (ASX:CGS) announced today that it has signed its first agreement with Abbott for the use of CogState's cognitive testing technology and associated services, in a Phase I clinical trial.
Abbott is a global, broad-based healthcare company devoted to discovering new medicines, new technologies and new ways to manage health. Abbott has a substantial central nervous system portfolio of drugs in development.
CogState already has sales contracts with leading companies in the field of central nervous system drug development, including companies such as Pfizer, GlaxoSmithKline, Merck and Alza Corporation (part of Johnson & Johnson), whereby CogState's technology is used in their clinical trials.
Mr Brad O'Connor, Chief Executive Officer of CogState, said: "CogState continues to be focussed on growing our customer base of pharmaceutical companies. This agreement represents another success for the company and is an excellent example of the hard work we have been putting into expanding sales in the US market."
Following today's announced agreement with Abbott, the total value of CogState's contracted future revenue exceeds A$2.1m. Contracted future revenues are revenue amounts to be recognised in coming periods, from signed agreements currently in place.